• LAST PRICE
    249.1500
  • TODAY'S CHANGE (%)
    Trending Up1.6500 (0.6667%)
  • Bid / Lots
    249.2200/ 1
  • Ask / Lots
    249.3100/ 1
  • Open / Previous Close
    249.6800 / 247.5000
  • Day Range
    Low 247.8800
    High 251.0500
  • 52 Week Range
    Low 198.6400
    High 258.4500
  • Volume
    1,144,272
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 247.5
TimeVolumeAMGN
09:32 ET67097250.57
09:34 ET15760250.03
09:36 ET11007250
09:38 ET3669249.05
09:39 ET9593249.14
09:41 ET6000248.24
09:43 ET8240248.24
09:45 ET4272248.34
09:48 ET9499248.2995
09:50 ET2730248.69
09:52 ET8438248.87
09:54 ET5753249.44
09:56 ET5897249.77
09:57 ET3300249.99
09:59 ET6945250.48
10:01 ET4846250.14
10:03 ET5905249.89
10:06 ET4416249.78
10:08 ET10062249.91
10:10 ET5674249.88
10:12 ET8518250.0522
10:14 ET5612250.11
10:15 ET4822250.45
10:17 ET3901250.6858
10:19 ET3455250
10:21 ET5494250.03
10:24 ET9241249.78
10:26 ET4722249.82
10:28 ET5149249.81
10:30 ET1477250.16
10:32 ET7456250.07
10:33 ET5021249.94
10:35 ET5682249.9
10:37 ET11061249.47
10:39 ET6221249.46
10:42 ET5925249.37
10:44 ET10349249.2454
10:46 ET2400249.17
10:48 ET6150249.2
10:50 ET9606248.793
10:51 ET11558248.59
10:53 ET22740248.89
10:55 ET4406249.19
10:57 ET6565249.315
11:00 ET6340249.32
11:02 ET5066249.29
11:04 ET4868249.22
11:06 ET4900249.09
11:08 ET6208249.24
11:09 ET8215249.54
11:11 ET3704249.26
11:13 ET8430249.3562
11:15 ET6608249.52
11:18 ET3377249.5487
11:20 ET6653249.5
11:22 ET6807249.137
11:24 ET5048248.97
11:26 ET5709248.85
11:27 ET2773248.455
11:29 ET3843249.05
11:31 ET5468249.53
11:33 ET7629249.71
11:36 ET6714250.005
11:38 ET5299249.935
11:40 ET2376249.89
11:42 ET5403250.18
11:44 ET3638249.8688
11:45 ET3385249.99
11:47 ET5161249.73
11:49 ET3246249.64
11:51 ET1956249.53
11:54 ET4146249.67
11:56 ET1180249.69
11:58 ET3107249.63
12:00 ET2052249.62
12:02 ET2106249.63
12:03 ET3301249.61
12:05 ET3400249.62
12:07 ET2600249.49
12:09 ET6154249.45
12:12 ET5415249.46
12:14 ET2484249.74
12:16 ET2003249.87
12:18 ET1908249.66
12:20 ET2323249.65
12:21 ET500249.7
12:23 ET1300249.66
12:25 ET2375249.67
12:27 ET1664249.55
12:30 ET400249.5
12:32 ET1300249.27
12:34 ET2700249.43
12:36 ET1249249.445
12:38 ET1860249.47
12:39 ET1569249.61
12:41 ET2293249.4
12:43 ET2000249.34
12:45 ET1383249.21
12:48 ET1300248.99
12:50 ET5362249.07
12:52 ET1894249.0199
12:54 ET1796249
12:56 ET2532249.06
12:57 ET1751249.21
12:59 ET1409249.45
01:01 ET1522249.46
01:03 ET1700249.55
01:06 ET3613249.4
01:08 ET3830249.35
01:10 ET3990249.51
01:12 ET1392249.36
01:14 ET1973249.435
01:15 ET1047249.37
01:17 ET3623249.04
01:19 ET3509248.95
01:21 ET1798248.97
01:24 ET2127249.2331
01:26 ET1700249.21
01:28 ET2135249.15
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAMGN
Amgen Inc
132.2B
24.5x
+0.08%
United StatesSNY
Sanofi SA
137.0B
19.9x
+7.84%
United StatesBMY
Bristol-Myers Squibb Co
162.2B
27.3x
+3.27%
United StatesAZN
AstraZeneca PLC
202.6B
-200.8x
-50.95%
United StatesGSK
GSK plc
111.7B
17.8x
+36.01%
United StatesVTRS
Viatris Inc
14.3B
85.0x
---
As of 2022-05-23

Company Information

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Contact Information

Headquarters
1 Amgen Center DrTHOUSAND OAKS, CA, United States 91320-1730
Phone
805-447-1000
Fax
805-447-1010

Executives

Chairman of the Board, President, Chief Executive Officer
Robert Bradway
Chief Financial Officer, Executive Vice President
Peter Griffith
Executive Vice President, General Counsel, Secretary
Jonathan Graham
Executive Vice President - Human Resources
Lori Johnston
Executive Vice President - Global Commercial Operations
Murdo Gordon

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$132.2B
Revenue (TTM)
$26.3B
Shares Outstanding
534.2M
Dividend Yield
3.11%
Annual Dividend Rate
7.7600 USD
Ex-Dividend Date
05-16-22
Pay Date
06-08-22
Beta
0.54
EPS
$10.16
Book Value
$12.00
P/E Ratio
24.5x
Price/Sales (TTM)
5.0
Price/Cash Flow (TTM)
14.5x
Operating Margin
30.44%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.